Dopamine, Plasma
The plasma dopamine test measures circulating dopamine, a catecholamine investigated in suspected phaeochromocytoma and paraganglioma. Dopamine-secreting paragangliomas are uncommon but may present with isolated dopamine elevation; the test is interpreted with plasma and urine metanephrines under strict collection conditions to minimise stress and posture artefact.
1
Biomarkers
Blood (plasma)
Sample
3–5 business days
Turnaround
Yes
Fasting
What is the Plasma Dopamine test?
The Dopamine, Plasma test quantifies circulating dopamine, a catecholamine measured predominantly to investigate suspected catecholamine-secreting tumours. It is part of the biochemical work-up of phaeochromocytoma and paraganglioma, conditions in which paroxysmal hypertension, headache, palpitations, and sweating prompt endocrine investigation. Dopamine-secreting paragangliomas are rarer than those secreting noradrenaline or adrenaline, but they do occur — particularly extra-adrenal paragangliomas — and may present with minimal or atypical symptoms because dopamine itself produces few cardiovascular effects. In this setting plasma dopamine complements plasma metanephrines and catecholamines, and a markedly elevated dopamine with relatively modest noradrenaline or adrenaline points to a dopamine-secreting lesion. Practitioners order this test in tandem with the wider catecholamine panel, not in isolation, and interpret it within the strict collection requirements that minimise artefactual elevation from stress, posture, or diet.
What does the Plasma Dopamine test measure?
Dopamine is a catecholamine neurotransmitter and precursor to noradrenaline and adrenaline, synthesised from tyrosine in sympathetic neurons, the adrenal medullae, and specific brainstem nuclei. In the periphery its role is limited — renal dopamine modulates sodium excretion and it has minor cardiovascular effects — and circulating plasma dopamine derives largely from sympathetic nerve spillover and traces of incomplete conversion in the adrenal. Its plasma half-life is on the order of one to two minutes, and local neuronal reuptake means that only a tiny fraction escapes into the circulation, making plasma dopamine a marker of catecholamine excess rather than of central dopaminergic function.
Plasma dopamine is measured in the context of suspected neuroendocrine tumours, primarily phaeochromocytoma and paraganglioma, where a secreting tumour can elevate circulating catecholamines. It is rarely elevated in isolation — adrenaline, noradrenaline, and their urinary metanephrines are more sensitive — but dopamine-secreting paragangliomas, though uncommon, may present with dopamine as the sole or dominant marker. Plasma dopamine is not used to assess central dopaminergic pathways (Parkinson disease, schizophrenia, attention disorders) or motivation; those are separate neuropsychiatric domains without a validated blood test.
Why is the Plasma Dopamine test ordered?
- Investigation of suspected phaeochromocytoma or paraganglioma in patients with paroxysmal or sustained hypertension, headache, palpitations, or diaphoresis
- Biochemical follow-up of an adrenal or extra-adrenal mass discovered incidentally or during staging for genetic syndromes (MEN2, von Hippel–Lindau, SDH mutations)
- Evaluation of patients with resistant hypertension or hypertensive crisis in whom secondary endocrine causes are being excluded
- Suspected dopamine-secreting paraganglioma, particularly extra-adrenal or head-and-neck lesions, where noradrenaline and adrenaline may be less elevated
- Serial monitoring after resection of a catecholamine-secreting tumour, where rising dopamine may indicate recurrence or metastatic disease
- Paediatric evaluation of suspected neuroblastoma in conjunction with urine catecholamines and metanephrines, though urine markers are the mainstay
- Clarification of borderline plasma or urinary metanephrine elevations when clinical suspicion for a secreting tumour remains
Sample collection and turnaround
Sample type
Blood (plasma)
Fasting required
Yes
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy via Quest. Patient must rest supine in a quiet room for at least 20–30 minutes before the draw; some protocols specify overnight fast and avoidance of caffeine, alcohol, and tyramine-rich foods for 24 hours beforehand. An indwelling catheter may be placed and left in situ during the rest period to minimise stress at the time of collection. Collect into chilled EDTA tube, separate plasma immediately (ideally within 30 minutes), and freeze. Tourniquet time should be minimised. Document time of day, position, and any medications. Refer to Quest's detailed collection protocol for catecholamines.
Specimen requirements
Minimum 1 mL EDTA plasma, separated and frozen within 30 minutes of draw. Ship frozen on dry ice. Note any delay in processing. The specimen is time- and temperature-sensitive.
What can affect Plasma Dopamine results?
Acute stress activates sympathetic outflow, raising circulating catecholamines; patient must rest supine for at least 20–30 minutes before the draw in a quiet environment.
Standing or sitting increases sympathetic tone and catecholamine spillover; dopamine is typically drawn supine to establish a resting baseline.
Foods containing tyramine (aged cheese, fermented products) and caffeine can transiently raise catecholamines; patients are often asked to fast or avoid specific foods before the draw.
Tricyclic antidepressants, sympathomimetics, alpha- and beta-blockers, and some antihypertensives can alter measured dopamine; a detailed drug history is essential and withholding interfering agents may be necessary.
Catecholamines are unstable at room temperature; plasma must be separated quickly, ideally within 30 minutes, and frozen to prevent enzymatic degradation.
Reduced renal clearance and altered catecholamine metabolism in chronic kidney disease can mildly raise plasma dopamine and confound interpretation in the setting of mild elevations.
What do Plasma Dopamine results mean?
Elevated
Markedly elevated plasma dopamine suggests a dopamine-secreting paraganglioma, particularly when noradrenaline and adrenaline are proportionately lower. Moderate elevations occur in classic phaeochromocytoma and some extra-adrenal paragangliomas, and should be correlated with imaging and plasma or urine metanephrines. Mild elevations may reflect collection artefact (stress, posture), medication interference, or chronic kidney disease rather than a tumour.
Normal
A normal plasma dopamine, when drawn under rigorously standardised conditions, is reassuring but does not exclude a catecholamine-secreting tumour if other markers are elevated or if the tumour secretes intermittently. Interpret with the full catecholamine and metanephrine panel.
Reduced
Low or undetectable plasma dopamine has no recognised clinical significance; dopamine is not used to diagnose deficiency states or central dopaminergic disorders.
Note: Plasma dopamine is exquisitely sensitive to pre-analytical variables — stress, posture, diet, and processing delay. A single mildly elevated value warrants repeat measurement under controlled conditions rather than immediate imaging. When dopamine is elevated, correlate with plasma metanephrines (more sensitive) and consider genetic evaluation for hereditary paraganglioma syndromes. Do not use plasma dopamine to assess central nervous system dopaminergic function.
Frequently asked questions
Plasma dopamine is measured in the work-up of suspected catecholamine-secreting tumours, primarily phaeochromocytoma and paraganglioma. Dopamine-secreting lesions are rarer but can present with isolated dopamine elevation, particularly in extra-adrenal paragangliomas.
How to access the Plasma Dopamine test
The Plasma Dopamine reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Lenders JWM, et al. Phaeochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. (2014)
- Eisenhofer G, et al. Biochemical diagnosis of phaeochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. (2003)
- Plouin PF, et al. European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. (2016)
- Peaston RT, Weinkove C. Measurement of catecholamines and their metabolites. Ann Clin Biochem. (2004)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.